Levoketoconazole - Strongbridge Biopharma

Drug Profile

Levoketoconazole - Strongbridge Biopharma

Alternative Names: 2S,4R-ketoconazole; COR-003; NormoCort; RECORLEV

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cortendo
  • Developer Strongbridge Biopharma
  • Class Chlorobenzenes; Dioxolanes; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Steroid 11-beta-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase inhibitors; Steroid 21 hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cushing syndrome

Most Recent Events

  • 31 Aug 2017 Levoketoconazole is still in phase III trials for Cushing's syndrome in countries worldwide, including USA, Canada, European Union, Israel, Serbia, Switzerland and Turkey (PO) (NCT01838551) (EudraCT2013-002133-37)
  • 07 Aug 2017 Strongbridge Biopharma completes enrolment in the phase III SONICS trial in Cushing's syndrome in Bulgaria, Canada, Czech Republic, Germany, Hungary, Poland, Serbia, Switzerland, Turkey (PO)
  • 23 Dec 2016 Strongbridge Biopharma plans the phase III LOGICS trial in Cushing syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top